Quanterix Corp.
- QTRX · Nasdaq
- Laboratory Analytical Instruments
- Billerica, MA
- 450 employees
- CIK 0001503274
Updated from SEC filings through
Top things to know
Executives
- Everett Cunningham Chief Executive Officer and joined our board of directors 10-K, 2026-03-02
- Masoud Toloue President & CEO 4, 2026-01-20
-
Jason F. Faessler Chief Financial Officer 4, 2026-07-16 - Vandana Sriram Chief Financial Officer 4, 2026-06-23
- Jason Faessler Chief Financial Officer and Treasurer 8-K, 2026-06-09
- James Edward Gute Jr. Chief Commercial Officer 4, 2026-09-17
What leadership is saying
“We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses. The actions we initiated last quarter to improve commercial performance, including reorganizing our teams and adding experienced leadership and discipline, should accelerate our execution in the fourth quarter and beyond”
Earnings press release (8-K Ex. 99.1), filed November 9, 2026
Quanterix Corp is a U.S. public company in laboratory analytical instruments (SIC 3826), headquartered in Billerica, MA. It trades as QTRX on Nasdaq. Revenue was $139M in the fiscal year ending December 31, 2025, +1.1% from the year before. It reported about 450 employees. Everett Cunningham is Chief Executive Officer and joined our board of directors.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $139M 10-K, 2026-03-02 | $137M 10-K, 2026-03-02 | $122M 10-K, 2026-03-02 | $106M 10-K, 2025-03-17 | $111M 10-K/A, 2024-12-26 |
| Operating income | -$126M 10-K, 2026-03-02 | -$52.6M 10-K, 2026-03-02 | -$46.0M 10-K, 2026-03-02 | -$104M 10-K, 2025-03-17 | -$56.5M 10-K/A, 2024-12-26 |
| SG&A | $138M 10-K, 2026-03-02 | $102M 10-K, 2026-03-02 | $89.1M 10-K, 2026-03-02 | $91.9M 10-K, 2025-03-17 | $92.9M 10-K/A, 2024-12-26 |
| Net income | -$107M 10-K, 2026-03-02 | -$38.5M 10-K, 2026-03-02 | -$28.4M 10-K, 2026-03-02 | -$99.6M 10-K, 2025-03-17 | -$55.5M 10-K/A, 2024-12-26 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Everett Cunningham Chief Executive Officer | Chief Executive Officer and joined our board of directors | 10-K, 2026-03-02 |
| Masoud Toloue | President & CEO | 4, 2026-01-20 |
| Ivana Magovčević-Liebisch, Ph.D., J.D. | Board member (per proxy) bio: President and Chief Executive Officer | DEF 14A, 2025-08-25 |
| Myla Lai-Goldman, M.D. | Board member (per proxy) bio: Former Chief Executive Officer and | DEF 14A, 2025-08-25 |
| Paul M. Meister | Board member (per proxy) bio: Co-Founder and Chief Executive Officer | DEF 14A, 2025-08-25 |
| Jason F. Faessler | Chief Financial Officer | 4, 2026-07-16 |
| Vandana Sriram | Chief Financial Officer | 4, 2026-06-23 |
| Jason Faessler | Chief Financial Officer and Treasurer | 8-K, 2026-06-09 |
| James Edward Gute Jr. | Chief Commercial Officer | 4, 2026-09-17 |
 Michael Francis Miller | Chief Technology Officer | 4, 2026-09-16 |
| Benjamin Meadows | Chief Commercial Officer | 4, 2026-06-12 |
| Michael Miller | Chief Technology and Products Officer | 8-K, 2026-05-26 |
| Anthony Catalano | Chief Operating Officer | 8-K, 2026-05-26 |
| Daniel Char Chief Legal Officer | Biopharma & MedTech Expert | Driving Growth, Innovation andCompliance in Complex Regulated Markets | Chief Legal Officer | 3, 2026-03-24 |
| Karen A. Flynn | Board member (per proxy) bio: Former Chief Commercial Officer | DEF 14A, 2025-08-25 |
| Scott Mendel | Board member (per proxy) bio: Former President and | DEF 14A, 2025-08-25 |
What Quanterix Corp does
We are a life sciences company transforming healthcare innovation by accelerating biomarker breakthroughs from discovery to diagnostics using our ultra-sensitive translational research and spatial biology instruments, consumables, and services. We continue to invest in pushing a paradigm shift in healthcare from an emphasis on later-stage treatment to a focus on earlier detection, monitoring, prognosis, and, ultimately, prevention.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 47.5 million (as of November 2, 2026) | 10-Q, November 9, 2026 |
|---|---|---|
| Public float | $239M (as of June 30, 2025) | 10-K, March 2, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 9, 2026 |
| Latest proxy statement | Meeting June 9, 2026 (filed April 24, 2026) | DEF 14A, April 24, 2026 |
| Auditor | Kpmg LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 13, 2026 | William P. Donnelly Director | Buy | 99,400 | $286K | Form 4, August 14, 2026 |
| May 12, 2026 | Benjamin Meadows Chief Commercial Officer | Buy | 3,500 | $10K | Form 4, June 12, 2026 |
| September 12, 2025 | Vandana Sriram Chief Financial Officer | Buy | 4,150 | $20K | Form 4, September 17, 2025 |
Recent 8-K events
- 8-K filed 2026-08-10
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-10
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-06-09
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-26
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-12
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-02
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-08
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-20
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-10
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Quanterix Corp
- What does Quanterix Corp do?
- In its own words, from Item 1 of its 10-K: "We are a life sciences company transforming healthcare innovation by accelerating biomarker breakthroughs from discovery to diagnostics using our ultra-sensitive translational research and spatial biology instruments, consumables, and services. We continue to invest in pushing a paradigm shift in healthcare from an emphasis on later-stage treatment to a focus on earlier detection, monitoring, prognosis, and, ultimately, prevention."
- What is Quanterix Corp's revenue?
- $139M for the fiscal year ending December 31, 2025, from its 10-K filed March 2, 2026.
- Is Quanterix Corp profitable?
- Quanterix Corp reported net income of -$107M for the fiscal year ending December 31, 2025.
- How many employees does Quanterix Corp have?
- About 450 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Quanterix Corp?
- Everett Cunningham, Chief Executive Officer and joined our board of directors, as named in a 10-K filed March 2, 2026.
- Who is the CFO of Quanterix Corp?
- Jason F. Faessler, Chief Financial Officer, as named in a 4 filed July 16, 2026.
- Where is Quanterix Corp headquartered?
- Billerica, MA.
- What is Quanterix Corp's stock ticker?
- QTRX on Nasdaq.
- What industry is Quanterix Corp in?
- Laboratory Analytical Instruments, SIC code 3826.
- What is Quanterix Corp's website?
- quanterix.com.
- When does Quanterix Corp report earnings next?
- November 9, 2026 at 08:30. Source: pg_future_events.
- Is Quanterix Corp a public company?
- Yes. Quanterix Corp files with the SEC under CIK 0001503274 and trades as QTRX.
- Who audits Quanterix Corp?
- Kpmg LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Quanterix Corp are outstanding?
- 47.5 million shares as of November 2, 2026, from its 10-Q filed November 9, 2026.
- What is Quanterix Corp's public float?
- $239M as of June 30, 2025, as reported on the cover of its 10-K filed March 2, 2026.
- How many business segments does Quanterix Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 9, 2026.
- When is Quanterix Corp's annual shareholder meeting?
- June 9, 2026, per its proxy statement (DEF 14A) filed April 24, 2026.
- Have Quanterix Corp insiders traded stock recently?
- Since September 12, 2025, officers and directors reported 0 open-market sales and 3 purchases worth about $316K on Forms 4 and 5. The most recent: William P. Donnelly (Director) bought 99,400 shares on August 13, 2026.